Press Releases
Search
-
17 Jul 2014
bioMérieux - Second-Quarter 2014 Business Review
Solid growth in first-half sales Up 7.9%, including BioFire and at constant exchange rates Up 4.2% like-for-like*, in line with the target for the year Up 3.5% on a reported basis Greater disparity be...
-
28 May 2014
The General Shareholders’ Meeting of bioMérieux approves the appointment of two new independent directors
Marcy l’Etoile, France, May 28, 2014 - The General Meeting of Shareholders of bioMérieux, a world leader in the field of in vitro diagnostics, today approved the appointment of two new independent dir...
-
05 May 2014
BioFire’s FilmArray® Gastrointestinal Panel Receives FDA Clearance
Marcy l’Etoile, France - May 5, 2014 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire, its new molecular biology affiliate, received U.S. Food and Drug A...
-
23 Apr 2014
First-Quarter 2014 Business Review
Sales: Up 7.9%, including BioFire and at constant exchange rates Up 4.1% like-for-like*, in line with the target for the year Continued stabilization in Western Europe, up 1.4%* Sustained solid growth...
-
15 Apr 2014
Alexandre Mérieux Assumes Role of bioMérieux CEO
Marcy l’Etoile (France), April 15, 2014 - Alexandre Mérieux will take on the role of Chief Executive Officer of bioMérieux and head its Management Committee. To step up the rollout of its strategic pl...
-
19 Mar 2014
bioMérieux - 2013 Financial Results
HIGHLIGHTS Objectives met Solid financial performance Sales up 4.6% at constant exchange rates and scope of consolidation Operating income before non-recurring items: €262 million, or 16.5% of sales F...
-
26 Feb 2014
bioMérieux strengthens its Clostridium difficile offer with the launch of VIDAS® C. difficile GDH
VIDAS® C. difficile GDH is the 100th assay for use on VIDAS® range VIDAS® C. difficile GDH is the only FDA-approved automated immunoassay parameter for GDH* detection * Glutamate dehydrogenase...
-
19 Feb 2014
BioFire Submits 510(k) Application to FDA for FilmArray® Gastrointestinal Panel
BioFire Diagnostics, LLC today announced that it has submitted the FilmArray Gastrointestinal (GI) Panel to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The comprehensive FilmArra...
-
27 Jan 2014
Appointment of Claire Giraut as bioMérieux’s Corporate Vice President & Chief Financial Officer
Marcy l’Etoile, France, January 27, 2014 — bioMérieux, a world leader in the field of in vitro diagnostics, announces that Claire Giraut has been appointed Corporate Vice President & Chief Financial O...
-
22 Jan 2014
Business Review for the year ended December 31, 2013
2013: solid 4.6% organic growth in sales At the top end of the target range announced early in the year Faster organic growth in North America and firmer business in Western Europe Sustained fast grow...
-
16 Jan 2014
bioMérieux finalizes acquisition of the U.S. company BioFire, specialized in molecular biology
Marcy l'Etoile, France, January 16, 2014 - bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has finalized its acquisition of 100% ownership in BioFire Diagnostics Inc...
-
05 Dec 2013
bioMérieux is Moving Forward to a New Molecular Biology Workflow Solution for Reference or Centralized Laboratories
Marcy l'Étoile, France, December 5th, 2013 - bioMérieux, a world leader in the field of in vitro diagnostics, has announced that it is moving a new step forward to its comprehensive automation solutio...
-
28 Nov 2013
bioMérieux Announces Termination of its Collaboration with Biocartis in Molecular Biology
Marcy l'Etoile, France, November 28, 2013 - bioMérieux, a world leader in the field of in vitro diagnostics, and Biocartis have mutually agreed to end their collaboration to develop and commercialize ...
-
29 Oct 2013
bioMérieux launches the Parvovirus B19 R-gene® kit, a new ARGENE® test for the detection and quantification of the three Parvovirus B19 genotypes
Marcy l'Étoile, France, October 28, 2013 - bioMérieux, a world leader in the field of in vitro diagnostics, has announced the launch of the Parvovirus B19 R-gene® kit, a new CE-marked ARGENE® real-tim...
-
23 Oct 2013
Business Review for the Nine Months Ended September 30, 2013
Sales: 2013 objective confirmed Very good third quarter with sales up 7.4%* (5.7%* excluding R&D-related revenue) Robust organic growth of 3.9% over the first nine months (3.3% excluding R&D-related r...